Share on StockTwits

PharMerica (NYSE:PMC) was upgraded by research analysts at Cowen and Company to an “outperform” rating in a report released on Wednesday.

PharMerica (NYSE:PMC) opened at 24.53 on Wednesday. PharMerica has a 1-year low of $12.15 and a 1-year high of $30.48. The stock’s 50-day moving average is $26.45 and its 200-day moving average is $27.06. The company’s market cap is $737.4 million.

PharMerica (NYSE:PMC) last released its earnings data on Tuesday, August 5th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. The company had revenue of $448.60 million for the quarter, compared to the consensus estimate of $432.70 million. During the same quarter in the previous year, the company posted $0.44 earnings per share. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, analysts predict that PharMerica will post $1.51 earnings per share for the current fiscal year.

PMC has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of PharMerica from a “neutral” rating to an “outperform” rating in a research note on Friday, August 8th. They now have a $31.40 price target on the stock. Separately, analysts at Barclays initiated coverage on shares of PharMerica in a research note on Thursday, July 17th. They set an “underweight” rating on the stock. Finally, analysts at ISI Group reiterated a “positive” rating on shares of PharMerica in a research note on Wednesday, July 2nd. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $28.85.

PharMerica Corporation is an institutional pharmacy services company, which services healthcare facilities and provides management pharmacy services to hospitals.

Receive News & Ratings for PharMerica Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica Co and related companies with Analyst Ratings Network's FREE daily email newsletter.